SCHEDULE 13G: Pathstone Family Office Reports Zero Beneficial Ownership in Cognition Therapeutics

Pathstone Family Office, LLC has filed a Schedule 13G indicating zero beneficial ownership of common stock in Cognition Therapeutics Inc.

Summary

• PATHSTONE FAMILY OFFICE, LLC filed a Schedule 13G with the SEC regarding its beneficial ownership of COGNITION THERAPEUTICS INC common stock.
• The filing states that PATHSTONE FAMILY OFFICE, LLC holds 0.00 shares of Cognition Therapeutics, representing 0% of the class.
• The reporting entity, PATHSTONE FAMILY OFFICE, LLC, is classified as an Investment Adviser (IA).
• The event date triggering the filing was May 23, 2024, with the statement signed and filed on February 4, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating zero ownership by the reporting entity. It has no direct positive or negative implications for the issuer's operations or financial health.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cognition Therapeutics Inc.'s future outlook.

Industry Context

This filing is a routine regulatory disclosure of institutional ownership. The reported 0% beneficial ownership indicates that Pathstone Family Office, LLC does not hold a significant stake in Cognition Therapeutics Inc., which is a factual statement of their current position and does not provide broader industry trend insights.

Stakeholder Impact

• No direct impact on shareholders, employees, customers, suppliers, or creditors as this filing merely states a lack of beneficial ownership by a specific entity and does not relate to the company's operations or financial performance.

Key Dates

Keywords

Schedule 13G, beneficial ownership, Cognition Therapeutics Inc, Pathstone Family Office LLC, common stock, SEC filing, investment adviser